SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) April 9, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On April 9, 1996, Biocontrol Technology, Inc.
announced that proxy returns for its Special
Shareholders' Meeting on this Thursday, April 11, have
exceeded 80% of those eligible to vote, and of those
voting to date, over 92% have voted in favor of the
Company's proposal to increase its number of authorized
shares.
The Company also stated that for security purposes
anyone wishing to enter the shareholders' meeting on
April 11 must show a picture ID.
Biocontrol further announced that the Food and
Drug Administration (FDA) has requested the Company to
submit a new 510(k) Notification with the data obtained
from the Diasensor 1000 noninvasive glucose sensor
production model.
The Company further announced today that the
Pennsylvania Securities Commission has requested a list
of Diasense, Inc. (subsidiary of BICO) shareholders.
The Company had already begun its own internal
investigation before being contacted by the PA SC, and
is voluntarily cooperating with their request to be
sure that the Company's directives on stock sales were
properly followed.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 9, 1996
